A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate

Trial Profile

A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
    • 18 Feb 2017 Results of 48 weeks data presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top